Note 3. Operating segments The consolidated entity continues to operate in one segment, being the clinical development in the field of both oncology and non-oncology in the pan-pacific region. The segment details are therefore fully reflected in the body of the annual report. Note 4. Income Consolidated 2025 2024 $ $ Interest income 8,502 6,930 R&D tax incentives ^ 2,820,831 2,400,276 Income 2,829,333 2,407,206 ^ The Research and Development Tax Incentive programme provides tax offsets for expenditure on eligible R&D activities. Under the programme, Noxopharm, having expected aggregated annual turnover of under $20 million, is entitled to a refundable R&D credit of 48.5% (2023: 48.5%) on the eligible R&D expenditure incurred on eligible R&D activities. One of the conditions the company must meet is ensuring more than 50% of total R&D activity costs will be incurred in Australia. The refundable R&D tax offset is accounted for under AASB 120 Accounting for Government Grants and Disclosure of Government Assistance. Note 5. Expenses Consolidated 2024 2024 $ $ Loss before income tax includes the following specific expenses: Corporate Administration expenses Corporate administration expenses 615,881 708,279 Audit, accounting and company secretarial fees 225,635 191,509 Insurances 23,276 75,927 Legal fees 6,630 26,721 ASX and filing fees 45,535 38,635 Marketing and advertising 21,955 57,938 938,912 1,099,009 Consulting, Employee and Director Expenses Employee related expenses 2,507,233 2,541,065 Superannuation and other employee related expenses 279,045 275,030 Director expenses (excluding executive directors) 150,000 150,000 Share-based payment expense - Noxopharm Limited ^ 63,990 - 3,000,268 2,966,095 Finance costs Interest and finance charges paid/payable 77,296 31,160 Interest on convertible notes 426,164 - 503,460 31,160 ^ Refer to note 25 for further information on share based payments. Annual Report 2025 33
RkJQdWJsaXNoZXIy MjE2NDg3